UK pharmaceutical giant AstraZeneca held talks with US rival Bristol Myers Squibb on a potential $400 billion merger on August 2, 2026, according to reports. The deal could create one of the world's largest pharmaceutical groups with a combined value near $400 billion.
No BS check run yet — press ⚖ to extract this story's claims and verify them against independent sources.
The deal could create one of the world’s biggest pharmaceutical groups with a combined value of nearly US$400 billion.
U.K. pharmaceutical giant AstraZeneca is considering a deal to merge with its U.S. rival Bristol Myers Squibb.
AstraZeneca holds talks with Bristol Myers Squibb on $400 billion megadeal, FT reports Reuters